Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin–angiotensin system blockade

Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension

(2015) William T. Cefalu et al.   DIABETES CARE

Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels

(2015) C. D. Sjöström et al.   DIABETES OBESITY & METABOLISM

Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors

(2014) Raymond V. Oliva et al.   Journal of the American Society of Hypertension

Placebo Effect and Efficacy of Nebivolol in Patients with Hypertension not Controlled with Lisinopril or Losartan: A Phase IV, Randomized, Placebo-Controlled Trial

(2013) Robert J. Weiss et al.   American Journal of Cardiovascular Drugs

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

(2013) Clifford J Bailey et al.   BMC Medicine

Blood Pressure Levels and Stroke: J-curve Phenomenon?

(2013) Jolanta Malyszko et al.   CURRENT HYPERTENSION REPORTS

Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

(2013) Serge A. Jabbour et al.   DIABETES CARE

Standards of Medical Care in Diabetes--2014

(2013)   DIABETES CARE

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

(2013) H. J. Lambers Heerspink et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years

(2013) J. P. H. Wilding et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

(2013) J. Bolinder et al.   DIABETES OBESITY & METABOLISM

2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults

(2013) Paul A. James et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Clinical Practice Guidelines for the Management of Hypertension in the Community A Statement by the American Society of Hypertension and the International Society of Hypertension

(2013) Michael A. Weber et al.   JOURNAL OF HYPERTENSION

Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review

(2013) Ann Colosia et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

(2012) Jan Bolinder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Mitral Valve in Hypertrophic Cardiomyopathy

(2011) Anna Woo et al.   CIRCULATION

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial

(2011) M. A. Nauck et al.   DIABETES CARE

Effect of a Reduction in Uric Acid on Renal Outcomes During Losartan Treatment

(2011) Yan Miao et al.   HYPERTENSION

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial

(2010) E. Ferrannini et al.   DIABETES CARE

Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Uric Acid and Cardiovascular Risk

(2008) Daniel I. Feig et al.   NEW ENGLAND JOURNAL OF MEDICINE